SHL is primed to exhibit at the Prefilled Syringe Seminar 2019 Tokyo from May 21-22. Visitors are welcomed to stop by SHL's stand to learn more about its innovations and industry-leading offerings.
As a long-standing exhibitor at this annual exhibition, which is hosted by the Parenteral Drug Association (PDA) Japan Chapter, SHL is set on presenting its strong pipeline of auto-injectors designed for high volume and high viscosity drug formulations. Top displays include the Bertha® auto-injector, developed to deliver highly viscous drugs in syringe volumes up to 2.25mL, and the Maggie® auto-injector, which is built with Needle Isolation Technology (NIT®) – an innovative solution that facilitates a cartridge-based architect while preventing sharps injuries.
SHL's Molly® family, including Molly® 1mL, Molly® 2.25mL and Molly® C, showcases SHL's self-developed, preconfigured technology for faster development timelines.
The rise of protein drugs and biologics in recent years have called for higher demands in SHL's drug delivery offerings. Executive Director of Business Development Mike Weng commented, "As a leading device manufacturer in the industry for 30 years, SHL is committed to innovation and research that advances our offerings in becoming biologics' best partner. This year, other than catching up on some industry talks with familiar faces, we are looking forward to expanding ties with potential partners."
Visit SHL at the Sola City Conference Center from May 21-22, where our experts will be on site to connect with visitors.
SHL Group is a world-leading solution provider in the design, development, and manufacturing of advanced drug delivery devices such as auto-injectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.
With over 4,000 employees worldwide, SHL Group consists of several distinct group companies:
SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.
SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.
SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.
For additional information, visit www.shl.group.